Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
Journal
JTO Clinical and Research Reports
Journal Volume
2
Journal Issue
9
Pages
100206
Date Issued
2021
Author(s)
Park K.
Tan D.S.W.
Su W.-C.
Cho B.C.
Kim S.-W.
Lee K.H.
Wang C.-C.
Seto T.
Huang D.C.-L.
Jung H.H.
Hsu M.-C.
Bogenrieder T.
Publisher
Elsevier Inc.
Type
journal article